P-17 · OPEN PROTOCOL · SURFACE LAYERMETABOLIC · EVIDENCE GAP · 6 MINUTES
The Measured Window
Incretins in the menopausal transition · a measurement plan, not a regimen
INGESTIBLE // MOLECULAR
◇ WHAT IT IS
This is not a protocol for taking a drug. It is a protocol for measuring one, and it exists because of a gap rather than a finding. Women in the menopausal transition are among the heaviest users of GLP-1 and GLP-1/GIP medication, and the registration trials were not built to answer anything specific about them. We searched: the precise literature query returns almost nothing. So there is no menopause-specific dosing schedule here, because there is no evidence for one, and anyone publishing one is extrapolating.
What there is, is a short list of things worth establishing before you start and watching while you continue — chosen because they are the exact places where the evidence is thin and the biology says a cost is plausible. Bone is the main one. The menopausal transition is already a period of accelerated bone loss; rapid weight reduction on top of it is a reasonable thing to watch rather than assume away. Muscle is the second. Neither has been measured properly in this population, which is precisely why you measure them in yourself.
The point is not to make you anxious about a medication that probably works. Efficacy appears to hold — 10 to 20 percent sustained loss in women over 65, with the cardiometabolic improvements intact. The point is that 'nobody has published harm' and 'we checked and found none' are different statements, and only one of them is true here.
One honest limit before you start, because we would rather say it than have you discover it: the first step depends on a physician agreeing to order a baseline DXA outside its standard indication, and some will decline — the guidelines they follow were written before this drug class existed at this scale. That is a real friction, not a formality, and it is the main reason this page scores low on deployability in our own audit. If your doctor says no, the fallback is not to argue; it is to establish the resistance substrate and the protein floor anyway, since those stand on evidence that has nothing to do with this dossier, and to revisit the scan question at the one-year mark with weight-loss data in hand.
◇ THE COMPONENTS
Baseline DXABone density before the first dose. Without a starting line, a later scan tells you a number but not a direction.
Bone remodelling markersThe faster signal. They move long before density does, which matters over a one-year window rather than a five-year one.
A body-composition method you will repeatDXA or equivalent. Consistency of method matters more than choice of method — two numbers from two instruments are not a trend.
Protein floor + resistance trainingThe only intervention here that is well evidenced everywhere else. It does not need this dossier's thin base to justify it.
A physician who knows both halvesMetabolic and menopausal. The interaction with hormone therapy has no controlled trial evidence, so it is managed case by case or not at all.
◇ HOW TO DEPLOY — DAILY TIMING
BEFORE THE FIRST DOSEBaseline DXA and bone remodelling markers, plus a body-composition reading you can repeat with the same method laterMeasurement
BEFORE THE FIRST DOSEEstablish resistance training and the protein floor while appetite is still intact — both get harder to start once the drug is suppressing intakeSubstrate
WITH YOUR PHYSICIANRaise the bone question explicitly, and the hormone-therapy interaction if it applies. Ask what will be monitored and on what schedule, given that the trials did not measure itClinical
THROUGHOUTHold protein and training. Appetite suppression makes adequate protein a deliberate act rather than an automatic oneSubstrate
AT ~12 MONTHSRepeat DXA and markers — the conservative reading of thin evidence, against the customary two-to-three-year interval, particularly at ~9% or more of body weight lostMeasurement
ONGOINGTreat any confident claim about incretins and menopause — reassuring or alarming — as unsupported until it cites a controlled trial in this population. As of this writing, almost none existJudgement
◇ WHAT CHANGES IN YOUR DAY
You replace an unanswerable question with an answerable one. 'Is this safe for me' has no trial answer in this population; 'what are we measuring, and how often' is something a clinician can act on today.
You get a personal dataset where the published one is missing. Two DXA readings twelve months apart tell you more about your own skeleton than the entire literature currently says about your demographic.
You stop reading silence as safety. Nobody publishing harm is not the same as somebody looking and finding none — and knowing the difference changes what you ask for.
2035 HORIZONPROJECTION · NOT PROVEN FACT
The subgroup analysis that already exists, unpublished
The pivotal trials enrolled large numbers of women in and past the menopausal transition. The data to answer most of this question may already sit inside trial databases, never stratified and never reported. That is the cheapest gap in this field to close, and the most likely to close first — probably by an academic group rather than a sponsor. Projection, not fact.
Bone endpoints as a condition of approval
If regulators begin requiring skeletal endpoints for drugs producing this magnitude of weight loss in older populations, this protocol becomes unnecessary — the answer would arrive from the trial rather than from your own DXA. Watch for it; do not wait for it.
⧗ OPERATOR ADVISORY
Informational, not medical advice. Semaglutide and tirzepatide are prescription pharmaceuticals; starting, dosing, and stopping are clinical decisions made with a licensed physician. This protocol contains no dosing guidance and is deliberately not a menopause-specific regimen — no evidence supports one. It lists measurements worth establishing and questions worth asking, so that a conversation with your doctor is better informed. Bone density, hormone therapy, and their interaction with incretin therapy are clinical matters requiring individual assessment.
◇ THE STANDARD // APPLIED TO THIS ASSET
◇ THE AUDIT — THIS ASSET, ON THE STANDARDCALIBRATED CERTAINTY = ∛(E · C · I)
Applies to healthy apex, not only to clinical deficit.
03 IMPLEMENTATION38
Survives a demanding calendar. Zero executive friction.
EMERGING
Signal is real but unproven. Watchlist, not protocol.
The sliders start at the OCCABUZZ assessment for this asset. Drag any layer to test the standard against our call.
The score is a geometric mean — a single failed layer collapses it. Excellence in two cannot rescue a gap in the third. That is why hype scores low and proven, feasible, broadly-applicable work scores high. The restraint is the product.